Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2754-2762

  Kwekkeboom, Dik J ^a   Teunissen, Jaap J ^a   Bakker, Willem H ^a   Kooij, Peter P ^a   De Herder, Wouter W ^a   Feelders, Richard A ^a   Van Eijck, Casper H ^a   Esser, Jan Paul ^a   Kam, Boen L ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; ENDOCRINE TUMOR; FEMALE; HEPATORENAL SYNDROME; HUMAN; ISOTOPE LABELING; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; REMISSION; WORLD HEALTH ORGANIZATION; CARCINOID; CLINICAL TRIAL; LIVER TUMOR; METASTASIS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ADENOMA, ISLET CELL; ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; DISEASE PROGRESSION; ENDOCRINE GLAND NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; TREATMENT OUTCOME;

EID: 21044451724     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.066     Document Type: Article

References (34)

1. Arnold R, Benning R, Neuhaus C, et al: Gastroenteropancreatic endocrine tumours: Effect of Sandostatin on tumour growth-The German Sandostatin Study Group. Digestion 54:72-75, 1993 (suppl 1)
2. Janson ET, Oberg K: Long-term management of the carcinoid syndrome: Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32:225-229, 1993
3. Ducreux M, Ruszniewski P, Chayvialle JA, et al: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95:3276-3281, 2000
4. 0]octreotide: The Rotterdam experience. Seminars Nucl Med 32:110-122, 2002
5. Anthony LB, Woltering EA, Espanan GD, et al: Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars Nucl Med 32:123-132, 2002
6. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12:941-945, 2001
7. Waldherr C, Pless M, Maecke HR, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:617-620, 2002
8. Paganelli G, Bodei L, Handkiewicz Junak D, et al: 90Y-DOTA-D-Phe1-Tyr3- octreotide in therapy of neuroendocrine malignancies. Biopolymers 66: 393-398, 2002
9. 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imag 30:207-216, 2003
10. Valkema R, Pauwels S, Kvols L, et al: Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTAO,Tyr3] octreotide in patients with somatostatin receptor positive tumours. Eur J Nucl Med Mol Imaging 30:5232, 2003 (suppl 2, abstr)
11. Waldherr C, Schumacher T, Maecke HR, et al: Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 29:S100, 2002 (suppl, abstr)
12. Reubi JC, Schar JC, Waser B, et al: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273-282, 2000
13. Erion JL, Bugaj JE, Schmidt MA, et al: High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model. J Nucl Med 40:223P, 1999 (suppl, abstr)
14. Kwekkeboom DJ, Bakker WH, Kooij PP, et al: [177Lu-DOTA0Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28:1319-1325, 2001
15. 3]octreotate. Eur J Nucl Med Mol Imaging 30:417-422, 2003
16. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
17. Otte A, Herrmann R, Heppeler A, et al: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26:1439-1447, 1999
18. Wichers M, Benz E, Palmedo H, et al: Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med 27:503-507, 2000
19. Faiss S, Pape UF, Bohmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689-2696, 2003
20. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1:727-740, 1983
21. Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189-1194, 1980
22. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992
23. Cheng PN, Saltz LB: Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86: 944-948, 1999
24. Van Hazel GA, Rubin J, Moertel CG: Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine. Cancer Treat Rep 67:583-585, 1983
25. Bukowski RM, Tangen CM, Peterson RF, et al: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 73:1505-1508, 1994
26. Ritzel U, Leonhardt U, Stockmann F, et al: Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 90:627-631, 1995
27. Andreyev HJ, Scott-Mackie P, Cunningham D, et al: Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 13:1486-1492, 1995
28. Neijt JP, Lacave AJ, Splinter TA, et al: Mitoxantrone in metastatic apudomas: A phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. Br J Cancer 71:106-108, 1995
29. Ansell SM, Pilot HC, Burch PA, et al: A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91:1543-1548, 2001
30. O'Toole D, Hentic O, Corcos O, et al: Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 80:79-84, 2004 (suppl 1)
31. Pelosi G, Bresaola E, Bogina G, et al: Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy-A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Human Pathol 27:1124-1134, 1996
32. La Rosa S, Sessa F, Capella C, et al: Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429:323-333, 1996
33. Jorda M, Ghorab Z, Fernandez G, et al: Low nuclear proliferative activity is associated with nonmetastatic islet cell tumors. Arch Pathol Lab Med 127:196-199, 2003
34. Gurevich L, Kazantseva I, Isakov VA, et al: The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract. Cancer 98:1967-1976, 2003